Novartis Boomray $900M Deal — Structure Breakdown

Novartis Pays Up to $900M for Boomray's Preclinical Radioligand Therapy

$900M in total deal value for a preclinical-stage radioligand therapy. On September 29, 2026, Novartis signed an exclusive license agreement with Boomray to develop and commercialize a preclinical radiopharmaceutical asset. The upfront payment, milestone breakdown, and royalty tiers remain undisclosed, but the headline number — $900M in total consideration — places this squarely among the richest preclinical radiopharm deals ever struck. This is Novartis doubling down on its post-Lutathera, post-Pluvicto thesis: that radioligand therapy is not a niche modality but a platform franchise, and that securing early-stage optionality at scale is cheaper than competing for Phase 2+ assets at auction.

Deal Structure Breakdown

The Boomray Novartis deal terms are deliberately opaque, which itself is informative. When both parties decline to break out the upfront, milestones, and royalties, it usually signals one of two things: the upfront is either embarrassingly large for the stage (putting pressure on future comparable deals) or strategically modest with the overwhelming majority of value loaded into development and commercial milestones. Given Novartis's pattern in radiopharm licensing — and its stated preference for milestone-heavy structures that tie capital deployment to clinical de-risking — the latter is more likely.

Let's run the math on what we can infer. Across preclinical radiopharm licenses tracked in the other Deal Benchmarks on Ambrosia, median upfront-to-total-deal-value ratios sit between 5% and 12%. At a $900M TDV, that implies an upfront somewhere in the $45M–$108M range. For a preclinical asset with no IND, that is aggressive but not unprecedented in radiopharm, where manufacturing complexity and target novelty command premiums that small-molecule preclinical deals rarely see.

The milestone structure is where the Boomray Novartis deal structure gets interesting. With the upfront likely consuming under 12% of TDV, roughly $790M–$855M sits in milestones. The question is how that splits between development milestones (IND filing, Phase 1/2 data readouts, pivotal trial initiation) and commercial milestones (first commercial sale, revenue thresholds). In recent Novartis radiopharm deals, commercial milestones have accounted for 55%–65% of total milestone pools. That would place $430M–$555M behind revenue-based triggers — money Boomray may never see if the asset stalls in Phase 2.

A $900M headline on a preclinical asset is not a $900M check. It is a $900M option chain. The real question is what Novartis paid for the first tranche of optionality — and whether that upfront adequately compensates Boomray for giving up rights this early.

Royalty terms are undisclosed, but radiopharm licensing benchmarks for preclinical assets on Solidus suggest mid-single-digit to low-double-digit tiered royalties are standard. Given Novartis's vertical integration in radiopharm manufacturing and its global distribution infrastructure, Boomray likely conceded on royalty ceiling in exchange for either a higher upfront or more favorable milestone triggers. That is a rational trade for a company without the capital or infrastructure to take a radioligand therapy through registration-enabling trials independently.

Competitive Context — Why Novartis and Why Preclinical Radioligand Therapy

Novartis has spent more than $15B building the most vertically integrated radioligand therapy franchise in pharma. The 2018 Advanced Accelerator Applications acquisition ($3.9B), the 2022 Mariana Oncology deal ($1B+), and the ongoing Pluvicto manufacturing scale-up have given Novartis cyclotron networks, CDMO capacity, and regulatory expertise that no competitor can replicate within a five-year window. Bristol Myers Squibb acquired RayzeBio for $4.1B in early 2024. Eli Lilly entered via Point Biopharma at $1.4B. AstraZeneca has been making smaller bets. But Novartis remains the category incumbent with the most to lose and the deepest infrastructure to exploit.

That infrastructure advantage is exactly why Novartis can afford to license preclinical assets at $900M TDVs. The marginal cost of advancing a radioligand therapy through Novartis's existing manufacturing and development pipeline is substantially lower than what a standalone biotech or a pharma newcomer would face. Novartis is not paying $900M for a molecule. It is paying for a target-molecule combination that slots into an existing operational machine — and for the right to keep competitors from accessing it.

The timing matters. The radiopharm deal market has compressed dramatically since mid-2025. Preclinical-stage targets that attracted $300M–$500M TDVs eighteen months ago are now commanding $700M–$1B. Three forces are driving this inflation: (1) a shrinking pool of novel, validated targets suitable for radioligand conjugation, (2) increasing regulatory clarity around alpha-emitter and next-generation beta-emitter payloads, and (3) a land-grab dynamic where pharma players are willing to overpay for exclusivity rather than risk being locked out of target classes entirely. Novartis is not immune to this dynamic — it is accelerating it.

Boomray's specific asset and target are categorized as "other" in therapeutic area, which suggests a non-oncology or novel-target application. If Boomray has developed a radioligand approach for a target outside the crowded PSMA, SSTR, and FAP space, that alone could justify premium economics. The scarcity value of differentiated radioligand targets is real, and Novartis's willingness to pay $900M at preclinical stage signals high internal conviction about target biology.

What This Means for Similar Assets

If you are a biotech founder or BD lead sitting on a preclinical radiopharmaceutical program, the Boomray Novartis deal structure resets your valuation expectations — but not uniformly.

Here is what you should internalize:

• TDV benchmarks for preclinical radiopharm have shifted upward. Eighteen months ago, the 75th percentile for preclinical radiopharm license TDVs was approximately $550M. This deal pushes the ceiling higher. But $900M is an outlier driven by Novartis-specific strategic urgency. Do not assume every buyer will match it.
• Upfront expectations remain constrained by stage. Even in a hot modality, preclinical upfronts rarely exceed $100M–$120M. The bulk of value remains milestone-contingent. If you are fundraising off a term sheet, discount the TDV by 70%–85% to estimate near-term cash impact.
• Target differentiation is the primary value driver. Programs targeting PSMA, SSTR, or other well-trodden biology will not command Boomray-level economics unless they offer a clearly differentiated payload, linker chemistry, or dosimetry profile. Novel targets — particularly outside oncology — carry scarcity premiums.
• Manufacturing readiness matters more than in other modalities. Buyers are increasingly diligencing radiopharm assets not just on biology and PK but on isotope supply chain, chelator stability, and GMP manufacturing feasibility. If your program cannot demonstrate a credible path to clinical-grade material, your TDV will be discounted 30%–50% versus comparable biology with manufacturing de-risking.

Run your own program through the Solidus benchmarking engine against 1,400+ comparable biopharma transactions to see where your deal terms fall relative to the Boomray-Novartis comp and the broader preclinical radiopharm dataset. The other Deal Benchmarks page provides modality-specific medians, quartile ranges, and upfront-to-TDV ratios that will sharpen your negotiating position.

The Bottom Line

The Boomray Novartis deal terms confirm what the market has been signaling for the past twelve months: radiopharmaceutical assets are being valued like platform bets, not single-indication shots on goal. A $900M TDV for a preclinical asset is aggressive by any historical standard, but it is rational within the context of Novartis's franchise strategy and the target scarcity dynamics reshaping the radiopharm landscape. For Boomray, the key question is execution — converting milestone optionality into cash by navigating the manufacturing and regulatory complexities that have tripped up more mature radiopharm programs. For the rest of the market, this deal is a price signal. Act accordingly.

Benchmark your own other deal against 1,400+ comparable transactions using the Ambrosia calculator. Input your modality, stage, and therapeutic area to generate custom upfront, milestone, and royalty comps in under 60 seconds.